Skip to main content
SpringerLink
Log in

Nonclinical Pharmacokinetics of a New Nonpeptide V2 Receptor Antagonist, Tolvaptan

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the pharmacokinetic profile of tolvaptan.

Method

The nonclinical pharmacokinetic profile of [14C]tolvaptan was evaluated in an absorption, distribution, and excretion study in rats after single oral administration. An in vitro protein binding study was also performed.

Results

The tolvaptan-derived radioactivity was rapidly absorbed and extensively distributed to all tissues in rats. The radioactivity levels were greatest in the gastrointestinal tract and liver, though the levels in the cerebrum, cerebellum and medulla oblongata were low. The serum and tissue concentrations of radioactivity, and serum concentration of tolvaptan in male and female rats showed a marked sex difference. The radioactivity was crossed the placenta and was distributed to the fetal tissues in pregnant rats. The milk showed 1.5–15.8-fold higher radioactivity than blood in lactating rats. The radioactivity mainly excreted into the feces via the biliary route. Tolvaptan binds extensively to plasma proteins (≥97.2%) in mouse, rat, rabbit, dog and human plasma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kondo K, Ogawa H, Yamashita H, et al. 7-Chloro-5hydroxy-1[2-methyl-4-(2-methylbenzoyl-amino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist. Bioorg Med Chem. 1997;7:1743–54.

    Article  Google Scholar 

  2. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860–7.

    PubMed  CAS  Google Scholar 

  3. Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288–94.

    PubMed  CAS  Google Scholar 

  4. Kato R, Yamazoe Y. Sex-specific cytochrome P450 as a cause of sex- and species-related differences in drug toxicity. Toxicol Lett. 1992;64/65:661–7.

    Article  Google Scholar 

Download references

Disclosures

None of the authors have any conflicts of interest associated with this study.

Author information

Authors and Affiliations

  1. Drug Safety Research Center, Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd, 463-10 Kagasuno, Kawauchi-cho, Tokushima, 771-0192, Japan

    Masayuki Furukawa, Ken Umehara & Eiji Kashiyama

Authors
  1. Masayuki Furukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ken Umehara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eiji Kashiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masayuki Furukawa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Furukawa, M., Umehara, K. & Kashiyama, E. Nonclinical Pharmacokinetics of a New Nonpeptide V2 Receptor Antagonist, Tolvaptan. Cardiovasc Drugs Ther 25 (Suppl 1), 83–89 (2011). https://doi.org/10.1007/s10557-011-6357-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-011-6357-x

Key words

Search

Navigation